Ken Griffin Actinium Pharmaceuticals, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.72 - $8.0 $68,284 - $317,600	39,700 Added 155.69%	65,200 $122,000
Q2 2024 Aug 14, 2024	BUY	$6.56 - $9.89 $10,496 - $15,824	1,600 Added 6.69%	25,500 $188,000
Q1 2024 May 15, 2024	BUY	$5.0 - $9.2 $29,500 - $54,279	5,900 Added 32.78%	23,900 $187,000
Q4 2023 Feb 14, 2024	SELL	$4.02 - $6.08 $37,787 - $57,152	-9,400 Reduced 34.31%	18,000 $91,000
Q3 2023 Nov 14, 2023	SELL	$5.91 - $7.37 $76,239 - $95,073	-12,900 Reduced 32.01%	27,400 $162,000
Q2 2023 Aug 14, 2023	BUY	$7.15 - $9.39 $23,595 - $30,987	3,300 Added 8.92%	40,300 $299,000
Q1 2023 May 15, 2023	SELL	$8.51 - $14.26 $488,474 - $818,524	-57,400 Reduced 60.81%	37,000 $349,000
Q4 2022 Feb 14, 2023	SELL	$7.05 - $14.41 $329,940 - $674,388	-46,800 Reduced 33.14%	94,400 $1.01 Million
Q3 2022 Nov 14, 2022	SELL	$4.81 - $8.48 $377,584 - $665,680	-78,500 Reduced 35.73%	141,200 $1.04 Million

8.31M

65.2K

21.7K

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $28.2M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.